Dr. Strumph is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2350 Merriman Way Rd
Moneta, VA 24121Phone+1 540-797-2147
Education & Training
UPMC Medical EducationFellowship, Pediatric Endocrinology, 1990 - 1994
Emory University School of MedicineResidency, Internal Medicine, 1986 - 1990
University of Rochester School of Medicine and DentistryClass of 1986
Certifications & Licensure
VA State Medical License 2010 - 2026
NC State Medical License 1994 - 2015
Publications & Presentations
PubMed
- 158 citationsSotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 DiabetesArthur T. Sands, Brian Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W. Bode
Diabetes Care. 2015-07-01 - 86 citationsInsulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytesCharles E. Sparks, Janet D. Sparks, Mary Bolognino, Arthur I. Salhanick, Paul S. Strumph
Metabolism. 1986-12-01 - 11 citationsEffects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin StudyBruce W. Bode, Eda Cengiz, R. Paul Wadwa, Phillip Banks, Thomas Danne
Diabetes Technology & Therapeutics. 2021-01-01
Press Mentions
Do the Risks of Sotagliflozin Outweigh Benefits for Type 1 Diabetes?September 19th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
